The CEO's total pay of approximately $5.1 million for 2025 is reasonable for a biotech chief executive running a $1.6 billion company with two drugs in Phase 3 development, and the pay structure is predominantly variable — a mix of stock options, time-vesting restricted stock units, and performance stock awards tied to three-year relative total shareholder return — meaning the bulk of compensation is genuinely at risk based on future stock and clinical performance. The prior Say on Pay vote cleared the 70% threshold at 71.1%, so no mandatory engagement-failure trigger applies, and the company has documented outreach to shareholders representing 62% of ownership ahead of this filing. While NTLA's stock has materially underperformed peers, the variable equity awards are structured so that executives will only realize meaningful value if the stock recovers and outperforms the Nasdaq Biotechnology Index, which is an appropriate alignment mechanism; the board-level accountability concern is addressed through AGAINST votes on qualifying directors.

The non-audit fees paid to Deloitte ($1,895 for database access) are a tiny fraction of the $1,198,013 in audit fees — well under the 50% threshold that would raise independence concerns — and Deloitte has served for approximately 11 years, which is well below the 25-year tenure trigger; as a Big 4 firm auditing a $1.6 billion market-cap company, Deloitte is clearly adequate for the engagement.